Pfizer has announced top-line results from two Phase 3 induction trials of tofacitinib 10 mg twice daily tablets in the Oral Clinical Trials for tofAcitinib in ulcerative colitis (OCTAVE) global clinical development program for the treatment of adults with moderate to severe ulcerative colitis. “We are encouraged by the results of the OCTAVE induction studies as ulcerative colitis is a chronic, and at times debilitating, disease that can be difficult to treat” said Rory O’Connor, MD, senior vice president and head of Global Medical Affairs, Global Innovative Pharmaceuticals Business … more

Earlier, Pfizer reported it has completed its acquisition of Hospira.“We are pleased that Hospira, the world’s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, is now part of Pfize,” said Ian Read, chairman and chief executive officer, Pfizer … more